Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Drugs giant AstraZeneca today warned profits would be at the lower end of its expectations after suffering setbacks in its efforts to produce new blockbuster treatments.
The UK's second-biggest medicine maker said an ovarian cancer drug called olaparib will not progress for further development after tests revealed it was unlikely to prove effective.
And the results of tests on drugs for patients with major depressive disorders were disappointing although research is still ongoing.
As a result, the group said it will take impairment charges of $381.5m (£246m) in the final quarter of 2011, which mean that its earnings were likely to be in the lower half of its range of forecasts.
Shares dropped 3% amid fears that Astra has relatively few new drugs to replace its existing stable such as Nexium for heartburn and schizophrenia drug Seroquel.
Astra, which employs around 11,000 staff in the UK, has operations across the UK at sites including Macclesfield and Wilmslow in Cheshire, Luton, Loughborough, Edinburgh and Brixham in Devon.
The pharmaceuticals industry is facing a challenging period as it looks for new products and faces the loss of exclusivity on existing drugs.
Astra has in recent years been hampered by problems with its newest medicines after it discontinued its motavizumab drug, used to prevent serious lung disease, leading to a $445m (£287.2m) accounting charge.
It also suffered delays in winning approval from US regulators for its heart medicine Brilinta. The US Food and Drug Administration requested further analysis into the blood-thinning pill before clearing the drug for sale.
PA
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments